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Effects of vesicular monoamine transporter inhibitors
on catecholamine release from bovine chromaffin cells
have been examined at the level of individual exocytotic
events. As expected for a depletion of vesicular stores,
release evoked by depolarizing agents was decreased
following 15-min incubations with reserpine and tetra-
benazine, as evidenced by a decrease in exocytotic fre-
quency and amount released per event. In contrast, two
reserpine derivatives, methyl reserpate and reserpic
acid, were much less effective. Surprisingly, the incuba-
tions also decreased the accompanying rise in intracel-
lular Ca21 evoked by depolarizing agents. Subcellular
studies revealed that reserpine and tetrabenazine at
concentrations near their Ki values not only could in-
crease cytoplasmic catecholamines but also could dis-
place Ca21 from vesicles. Furthermore, transient expo-
sure to tetrabenazine and reserpine, but not methyl
reserpate and reserpic acid, induced exocytotic release
of catecholamines. Reserpine induced a rise in intracel-
lular Ca21, as detected by whole-cell measurements with
Fura-2. It could induce exocytosis, albeit at a lower fre-
quency, in Ca21-free solutions, supporting an internal
Ca21 source. Depletion of endoplasmic reticulum and
mitochondrial Ca21 pools did not eliminate the reser-
pine-activated release. These results indicate that vesic-
ular Ca21 can play an important role in exocytosis and
under some conditions may be involved in initiating this
process.
Vesicles in neurons and secretory cells frequently contain
large amounts of Ca21 (1–4). For example, the vesicles of
chromaffin cells isolated from the adrenal medulla contain
nearly 60% of the total Ca21 contained within the cell (5).
Vesicular Ca21 is incorporated during vesicle biogenesis at the
Golgi-endoplasmic reticulum apparatus (6, 7). Furthermore,
vesicles can take up Ca21 via a Na1/Ca21 exchanger. Calcium
is strongly retained in chromaffin vesicles (8) because it is
associated with the chromogranins, a group of acidic, soluble
proteins. Chromogranins also associate with catecholamines,
and this composite association allows maintenance of vesicular
stores within the small volume of the vesicle.
The high concentration of vesicular Ca21 is of interest since
Ca21 plays a central role in initiating the fusion between the
vesicle and plasma membrane during exocytosis. Vesicular
Ca21 is located at the precise location where exocytosis is
occurring. If it can be mobilized, it would clearly play a major
role in modulating release. Lowering of vesicular Ca21 de-
creases exocytotic rates in both pancreatic cells (1) and acetyl-
choline-containing neurons (2). These results suggest that ve-
sicular Ca21 may frequently play a role in triggering
exocytosis. In a prior work, we have shown that vesicular Ca21
in bovine chromaffin cells can be mobilized by exposure to
agents that cause an alkalinization of the vesicle interior (9).
Normally, the intravesicular pH is 5.5, a value that promotes
the association of the intravesicular contents (7). Alkaliniza-
tion of isolated vesicles with methylamine caused Ca21 efflux.
Similar results were found with amphetamine exposure, a
phenethylamine that can alkalize vesicles (10). In intact cells,
these agents increased both Ca21 and catecholamine in the
cytoplasm. With amphetamine, the amount of Ca21 displaced
from the vesicles was sufficient to trigger exocytosis.
In this work, we have taken a different approach to disrupt-
ing association vesicular contents. We have examined the ef-
fects of inhibitors of the vesicular monoamine transporter on
Ca21 mobilization from vesicles and its effects upon release.
Reserpine, tetrabenazine, and two reserpine derivatives were
employed, all of which are specific inhibitors of catecholamine
transport (11–14). The results indicate that VMAT1 inhibitors
are capable of mobilizing vesicular Ca21 in addition to cate-
cholamine, that the effects of this mobilization are reflected in
altered characteristics of stimulated secretion, and that inhib-
itors with high affinity for VMAT can trigger exocytosis in the
absence of any other secretagogue.
EXPERIMENTAL PROCEDURES
Cultured Chromaffin Cells—Primary cultures of bovine adrenal
chromaffin cells were prepared as described previously (15). Briefly,
chromaffin cells were isolated from several bovine adrenal glands by
digestion with collagenase and density gradient centrifugation through
Renografin to obtain the epinephrine-enriched fraction. Cells were
plated at a density of 3 3 105 cells/35-mm diameter plate and main-
tained in a controlled atmosphere with 5% CO2 in air at 37 °C. Exper-
iments were performed during days 3 through 7 of culture.
Electrodes and Electrochemical Procedures—Microelectrodes were
fabricated by sealing 6-mm diameter carbon fibers (Thornel T-650,
Amoco Corp., Greenville, SC) in glass as described previously (16). The
electrodes were polished at a 45° angle on a diamond dust-embedded
micropipette-beveling wheel (Sutter Instrument Co., Novato, CA) and
soaked in isopropyl alcohol before use. Electrodes were calibrated using
a flow-injection apparatus. Amperometry employed an Axopatch 200B
(Axon Instruments, Foster City, CA) in the voltage clamp mode with the
whole cell configuration (b 5 1). The low pass filter was set to 10 kHz,
and the gain was 10 mV/pA for Ca21-containing buffers and 20 mV/pA
for all others. The applied potential was 1650 mV with respect to a
sodium-saturated calomel electrode. The amperometric signal was dig-
itized (PCM-2, Medical Systems Corp., Greenvale, NY) and stored on
video cassette recorder tape.
Amperometric data recorded at cells were played back into a PC with
commercially available hardware and software (Cyberamp 320 and
Axotape, Axon Instruments). Normally, current records were digitally
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filtered at 400 Hz before analysis. Individual spikes (S/N 5 5) were
located by locally written software. However, after 15-min incubations
with VMAT inhibitors, spikes were sufficiently smaller so that 10-Hz
filtering was required to detect the spikes. This over-filtering does not
affect the area of each spike (Q), a measure of the quantal size. Data
sets were analyzed by single factor ANOVA for statistical significance.
Single Chromaffin Cell Experiments—Before the experiments, the
cells were washed three times and then maintained in a pH 7.4 buffer
on the culture plate. The primary buffer contained 145 mM NaCl, 5 mM
KCl, 11.2 mM glucose, 10 mM HEPES, 2 mM CaCl2, and 1 mM MgCl2z6
H20. Chemical stimulations and incubations of the cells were performed
with the desired agents dissolved in this solution for the Ca21-contain-
ing experiments. Ca21-free experiments were performed in the primary
buffer that was made without the addition of CaCl2. In every case, the
application of buffers alone via pressure ejecting did not elicit release of
catecholamine from the cells nor did it cause changes in [Ca21]i.
The culture plate was placed on the stage of an inverted microscope
(Axiovert 35, Zeiss, Eastern Microscope, Raleigh, NC). A pressure ejec-
tion device (Picospritzer, General Value Corp., Fairfield, NJ) connected
to a micropipette with a 10-mm diameter tip was used to apply secre-
tagogues onto individual cells. The carbon-fiber microelectrode and
micropipette were mounted on micromanipulators (Patch Clamp Driver
PCS-250, Burleigh, Instruments Inc., Fishers, NY). The micropipette
was positioned 25–35 mm from the cell, and the microelectrode was
positioned firmly against the cell surface. In experiments that involved
incubation of the cells, cells were first tested by pressure ejection of
nicotine (typically 4 times for 4–5 s with 2 min between each ejection)
followed by the addition of drug and incubation for 15 min. For exper-
iments involving the transient exposure of cells to drugs, the drug of
interest was applied via pressure ejection for 4 to 5 s. Cytoplasmic
catecholamine levels were determined by incubating the cells with the
indicated drug for 15 min and then permeabilizing it via the pressure
ejection of 10 mM digitonin (17).
In Ca21-free buffer, pressure ejection of 10 mM caffeine was used to
test the exocytotic viability of the cells (18). To chelate intracellular
Ca21, the cells were incubated in a Ca21-containing buffer containing
50 mM BAPTA-AM for 10 min (procedure from Ref. 19). Cells were then
rinsed with a Ca21-free buffer and maintained in that solution while
agents were pressure-ejected onto the cells. To investigate thapsigar-
gin-sensitive stores, cells were permeabilized by incubation with 1 mM
digitonin in Ca21-free buffer for 2 to 5 min followed by a 5-min incuba-
tion with 100 nM thapsigargin in the Ca21-free buffer. The cells were
then rinsed, and release was tested in Ca21-free buffer (the procedure
was modified from Ref. 20). To investigate Ca21 stores in mitochondria,
cells were permeabilized by incubation with 1 mM digitonin for 4 min to
allow entry of 50 mM ruthenium red. After 5 min, the cells were stim-
ulated via pressure ejection (procedure modified from Ref. 3).
Fura-2 Ca21 Measurements—Fura-2 AM was dissolved in a 10 ml of
10% Pluronic® F-127 and 40 ml of dry Me2SO mixture. Chromaffin cells
were incubated in a buffer solution containing 1 mM Fura-2 AM and
0.1% bovine albumin for 20 min at 22 °C. The cells were then rinsed
with fresh buffer, and the Fura-2 AM was allowed to de-esterify for 20
min followed by two additional washes with buffer.
Whole-cell fluorescence measurements were made with a pinhole
that allowed light from a 27-mm diameter spot on the plate to be
detected by a photomultiplier tube (EMPIX Photometer System, Mis-
sissaugua, Canada). Cells were alternately excited at 340 6 7.5 and
380 6 7.5 nm, whereas emission at 510 6 10 nm was measured. Light
was collected through a 403 oil immersion objective (Carl Zeiss Fluar
403, Thornwood, NY). To reduce photobleaching, excitation light from
the Xenon arc lamp passed through a 0.5 neutral density filter (30%
transmission) positioned between the arc lamp and the 403 objective.
Ratios of F340/F380 were determined at 750-ms intervals.
Ca21 in Isolated Vesicles—Vesicles from epinephrine-containing cells
were isolated and purified as described previously (9, 21). The vesicle
pellet was resuspended in 70 ml of Ca21-free isotonic buffer without a
chelating agent. The vesicles were incubated with the desired com-
pound for 10 min and centrifuged for 5 min, and pelleted vesicles were
resuspended in the Ca21-free isotonic buffer. Calcium levels were de-
termined by atomic absorption spectroscopy (Instrumental Laboratory
S-12 AA/AE Spectrophotometer, l 5 422.7 nM; the gas mixture was
approximately 5:1 air to acetylene). LaCl3 was added to obtain a final
concentration of 1% (w/v) to minimize interference by anions such as
phosphates. Standard additions of Ca21 were utilized to determine the
mol of Ca21/mg of protein.
Materials—Nicotine and BAPTA-AM were obtained from RBI
(Natick, MA). Fura-2 AM and Pluronic® F-127 were purchased from
Molecular Probes (Eugene, OR). Tetrabenazine was from Fluka (Buchs,
Switzerland). Methyl reserpate and reserpic acid were prepared as
described (22). Penicillin/streptomycin was obtained from the
Lineberger Cancer Research Center (Chapel Hill, NC). The chromaffin
cell culture medium was Dulbecco’s modified Eagle’s medium/Ham’s
F-12 medium from Life Technologies, Inc. Collagenase was acquired
from Worthington Chemicals (Freehold, NJ). Renografin-60 was from
Squibb Diagnostics (New Brunswick, NJ). Dimethyl sulfoxide was pur-
chased from Mallinckrodt Chemical Works. All other chemicals were
purchased from Sigma. All solutions were prepared in distilled, deion-
ized water (Mega Pure System MP-3A, Corning Glass).
RESULTS
Effects of Incubation with VMAT Inhibitors on Nicotine-
evoked Catecholamine Release—To evaluate the effects of incu-
bation with VMAT inhibitors on subsequent release, nicotine
was employed as the secretagogue. Individual cells were stim-
ulated 4 times with 50 mM nicotine (with 2-min intervals be-
tween each 5-s stimulation), and catecholamine release was
monitored. The drug of interest was then added to the buffer.
After 15 min, another round of nicotine stimulations was per-
formed as described above. In the absence of drug, no spikes
were observed in the 15-min interval between nicotine stimu-
lation (Fig. 1a), and the second series of nicotine stimulations
evoked a similar spike frequency and average quantal size to
that obtained before the 15-min interval (Fig. 2). In contrast,
incubation with 90 nM reserpine evoked spikes during the first
8 to 10 min of incubation, and the frequency of spikes was lower
(Fig. 1B). Analysis of the spikes revealed that this incubation
significantly lowered the average quantal size as well as the
spike frequency evoked by the second nicotine exposure (Fig.
2).
Similar experiments were conducted with a lower dose of
reserpine, with tetrabenazine, another VMAT2 inhibitor at two
different doses, and with structural analogues of reserpine,
methyl reserpate and reserpic acid. The latter two compounds
did not evoke spikes or alter subsequent depolarization-in-
duced release at doses up to 500 nM. Even at 1 mM they only had
slight effects. However, at both concentrations tested, reser-
pine and tetrabenazine elicited release during the first few
minutes of the incubation period (see below). Additionally, the
frequency of nicotine-evoked spikes and mean quantal size
(Fig. 2) were significantly reduced following incubation with all
VMAT inhibitors. Incubation effects with amphetamine were
also examined. As with the VMAT inhibitors, it induced release
during the incubation interval, diminished quantal size, and
decreased the frequency of subsequent nicotine-evoked release
(Fig. 2).
Effect of Incubation with VMAT Inhibitors on Intracellular
Ca21 Response to K1 Stimulation—The effect of incubation
with VMAT inhibitors and amphetamine on [Ca21]i was exam-
ined by monitoring the fluorescence ratio of intracellular
Fura-2, alternately excited at two wavelengths (340 and 380
nm). In this case, 60 mM K1 was used as a secretagogue, an
agent that causes robust changes in the fluorescence ratio,
indicating elevated intracellular Ca21 (23). For cells that were
not exposed to VMAT inhibitors, the rise in [Ca21]i evoked by
60 mM K1 was unchanged compared with that seen before the
15-min incubation (Fig. 2C). In contrast, the rise in [Ca21]i was
diminished on the second K1 exposure following incubation
with reserpine and tetrabenazine at the doses shown (Fig. 2C).
The decreased frequency of evoked spikes after incubation cor-
relates very well with the decreased [Ca21]i evoked by a depo-
larizing stimulus. Identical results were obtained with amphet-
amine (Fig. 2C).
Effect of VMAT Inhibitors on [Ca21] in Isolated Vesicles—To
explore the effects of reserpine, tetrabenazine, reserpic acid,
and methyl reserpate on [Ca21]vesicle, the Ca
21 content of iso-
lated vesicles was examined by atomic absorption spectroscopy
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after exposure to these inhibitors. Isolated vesicles were main-
tained in Ca21-free buffer with or without VMAT inhibitors for
a total of 15 min. Ca21-free buffer was utilized to replicate the
extremely low amounts of Ca21 in the cytoplasm of the cell. The
vesicular content found, 124.9 nmol of Ca21/mg of protein, is
quite similar to those found previously for untreated vesicles:
125 6 15 nmol of Ca21/mg of protein (24) and 112 6 6.3 nmol
of Ca21/mg of protein (25). Reserpine (9 and 90 nM) as well as
tetrabenazine (50 nM and 10 mM) caused a decrease in
[Ca21]vesicle (Fig. 3A). These results indicate that reserpine and
tetrabenazine, like amphetamine (9), are capable of causing
Ca21 displacement during extended exposure. Methyl reser-
pate and reserpic acid, both at 1 mM, did not cause significant
changes in the Ca21 content of isolated vesicles.
FIG. 1. Exocytotic rate of single
chromaffin cells exposed to nicotine
(NIC) at 15-min intervals measured
by amperometry. Initially, each cell was
exposed 4 times to a 5-s pressure ejection
of 50 mM nicotine. In A, the cell was left
untreated for 15 min and stimulated
again with nicotine. The inset is a repre-
sentative amperometric trace induced by
nicotine. In B, 90 nM reserpine (RES) was
added to the culture plate after the initial
nicotine exposure, and then it was ex-
posed to nicotine again after 15 min. In-
dividual spikes were summed in 30-s in-
terval bins.
FIG. 2. Effects of VMAT inhibitors on quantal size, spike frequency, and D[Ca21]i. Cells were stimulated with nicotine before and after
a 15-min incubation period as described in Fig. 1. During the incubation period, the drug indicated was present in the buffer. Amperometric spikes
were characterized with respect to quantal size (Q) and spike frequency in the minute immediately after nicotine application (spikes/minute). The
data shown in A are the average quantal size after the 15-min interval normalized by the values obtained initially. In this way, each cell serves
as its own control. In B, the data is the average spike frequency normalized in the same way. A minimum of 450 spikes after drug application were
used in this analysis. Measurements of internal Ca21 were made with Fura-2 during exposures to K1 before and after a 15-min interval in which
the drug indicated was placed in the buffer are shown in C. All results are the average ratios from at least four cells, and the error bars represent
the S.E. All ratios with added drug are statistically significant from the control as analyzed by ANOVA (p , 0.04, degrees of freedom .10). The
mean spike characteristics evoked by 50 mM nicotine were typical of previous reports (20 ms, 1.42 pC (corresponding to 4.4 3 106 molecules), and
80 pA, for t1⁄2, quantal size, and amplitude, respectively, when filtered at 400 Hz). RES, reserpine; TBZ, tetrabenazine; AMPH, amphetamine.
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Cells Incubated with VMAT Inhibitors Increased Cytoplas-
mic Catecholamine Content—Cells were incubated with the
drug of interest in Ca21-containing buffer for 15 min. To eval-
uate the effects of VMAT inhibitors on cytoplasmic cate-
cholamine levels, the cells were then transferred to Ca21-free
buffer and permeabilized with 10 mM digitonin delivered from a
pressure ejection pipette for 5 s. In some cases, multiple expo-
sures to digitonin were required to induce membrane perme-
abilization. Under these conditions, the cytoplasmic contents of
the cell can leak out, and the electroactive species can be
detected with an adjacent carbon-fiber electrode (26). The dig-
itonin-induced efflux of cytoplasmic catecholamine is prolonged
over several seconds, quite different from the sharp concentra-
tion spikes observed during exocytosis. When untreated cells
were permeabilized with digitonin, no cytoplasmic cat-
echolamines were detected (9). However, measurable cytoplas-
mic catecholamines were present in cells incubated with both
doses of tetrabenazine and reserpine (Fig. 3B). For reserpine
and tetrabenazine, the detected amount of cytoplasmic cate-
cholamine was concentration-dependent. For reserpine, a 9 nM
concentration (n 5 5) resulted in (5.52 6 1.65) 3 107 molecules
being detected, and a 90 nM concentration (n 5 4) released
(8.03 6 0.21) 3 107 molecules. For tetrabenazine, a 50 nM
concentration (n 5 4) resulted in (5.46 6 1.09) 3 106 molecules
being detected, and a 10 mM concentration (n 5 4) released
(2.47 6 0.43) 3 107 molecules. Note the strong correlation
between amounts of Ca21 and catecholamine displaced.
Exocytosis Induced by Transient Exposure to VMAT Inhibi-
tors—Reserpine pressure ejected onto intact cells for 5 s evoked
exocytosis with a frequency that was concentration-dependent
(Fig. 4). Concentrations of tetrabenazine lower than 10 mM did
not elicit release (Fig. 4). To determine if the lipophilicity of
reserpine was a factor in inducing the release of vesicles from
chromaffin cells, two derivatives were employed: 1 mM methyl
reserpate and 1 mM reserpic acid. These drugs are less effective
than reserpine in inhibiting transport of catecholamines by
VMAT. Neither is a substrate for transport by VMAT, and both
are relatively impermeant when compared with reserpine (12,
27). The reserpine derivatives (1 mM) generated only one or two
spikes when pressure-ejected onto the cells. Most cells did not
respond to this transient exposure to the reserpine derivatives.
Effect of Transient Exposure to VMAT Inhibitors on [Ca21]i—
The effect of pressure ejection of the VMAT inhibitors on
[Ca21]i was examined by monitoring the fluorescence of intra-
cellular Fura-2 alternately at two excitation wavelengths (340
and 380 nm). Transient exposure to 90 nM reserpine caused a
brief increase in [Ca21]i (Fig. 5A), although the change was
lower than that evoked by the pressure ejection of 60 mM K1 in
Ca21-containing medium. Ca21 effects induced by tetrabena-
zine (Fig. 5B), methyl reserpate, and reserpic acid were not
detectable. Additionally, reserpine-evoked increases in [Ca21]i
were not observed in Ca21-free medium.
External Ca21 Requirement for Reserpine-induced Exocyto-
sis—To test whether external calcium was required for the
release response to transient reserpine exposure, this Ca21
source was eliminated by chelation with 0.5 mM EGTA for 5
min, and either reserpine or caffeine was applied onto the cell
via pressure ejection for 5 s. Caffeine evokes release of Ca21
from internal thapsigargin-sensitive stores, serving as a posi-
tive control (Table I). Reserpine also induced exocytosis under
these conditions, implying that external Ca21 facilitates more
frequent release, but is not required for reserpine-induced re-
lease. To chelate internal Ca21, cells were incubated for 10 min
with 50 mM BAPTA-AM and rinsed with a Ca21-free buffer
FIG. 3. Effects of incubation with VMAT inhibitors on intravesicular Ca21 and cytoplasmic catecholamine content. A, Ca21
measurements. Isolated chromaffin vesicles were incubated with the indicated drug in Ca21-free buffer for 15 min. The control cells were left
untreated for that time period. The Ca21 amounts remaining in the vesicles were determined with atomic absorption spectroscopy and were
normalized to the amount of vesicular protein. Three samples were examined for each condition, and at least two measurements per sample were
made. Only drugs that induced a statistically significant change are shown. The values (averages 6 S.E.) are the amount of Ca21 content decreased
relative to vesicles incubated with no drug. B, catecholamine measurements. Whole cells were incubated with the indicated drug in a Ca21-
containing buffer for 15 min. Then 10 mM digitonin was pressure ejected onto the cell, and catecholamine liberated from the cytosol was measured
as the integral of the current measured with an adjacent carbon-fiber microelectrode. RES, reserpine; TBZ, tetrabenazine.
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solution. Caffeine- and reserpine-induced exocytosis decreased
(Table I). This reduction in spike frequency indicates that an
internal Ca21 source is involved in exocytosis. No VMAT-in-
duced changes in internal Ca21 concentration were detectable
by Fura-2 measurements in the absence of external Ca21 (data
not shown).
Internal Ca21 Source for Reserpine-induced Exocytosis—To
determine which internal store of Ca21 could be involved in the
D[Ca21]i and subsequent release of catecholamine induced by
reserpine, pharmacological intervention was employed. Thap-
sigargin is an inhibitor of the sarco(endo)plasmic reticulum
calcium ATPase (SERCA) family of intracellular Ca21 pumps,
which account for Ca21 uptake into inositol 1,4,5-triphospate,
as well as caffeine-sensitive Ca21 stores in bovine chromaffin
cells (20). Cells were permeabilized with 1 mM digitonin, treated
with 100 nM thapsigargin for 5 min, and then maintained in
Ca21-free buffer. Pressure ejection of reserpine (9 nM) induced
several vesicles to be released, whereas caffeine (10 mM) caused
a few smaller amplitude spikes to be detected (Fig. 6B). This
result indicates that the source of Ca21 for reserpine-induced
release is different from the thapsigargin-sensitive store. Next,
the mitochondrial store of Ca21 was investigated with ruthe-
nium red, an inhibitor of Ca21 transport in mitochondria (3).
Cells were permeabilized with digitonin and then incubated
with 50 mM ruthenium red for 4 min. Pressure ejection of 9 nM
reserpine evoked several concentration spikes (Fig. 6C), reveal-
ing that mitochondrial Ca21 stores were not necessary for the
evoked release. These results provided pharmacological evi-
dence that the vesicles were one of the organelles that could
contain the reserpine-sensitive Ca21 store.
DISCUSSION
A growing body of evidence supports the notion that storage
vesicles serve as important depots for intracellular calcium and
that storage and release of vesicular calcium may play a sig-
nificant role in exocytosis from neurons and other secretory
cells. Chromaffin storage vesicles contain nearly 60% of the
total Ca21 contained within the cell (5). Several channels and
pumps have been observed in storage vesicle membranes (28),
including Na1/Ca21 exchange activity (3) and a Ca21-H1 anti-
porter (29). In PC12 cells, Ca21 influx due to plasma membrane
depolarization appears to trigger an intravesicular increase in
pH, possibly via exchange of vesicular protons for cytoplasmic
Ca21 (30). Manipulation of intracellular Ca21 stores can have
dramatic effects on the release response, possibly affecting both
FIG. 4. Concentration dependence
of spike frequency on VMAT inhibi-
tor concentration. Reserpine or tetra-
benazine were applied onto individual
cells by pressure ejection, and the evoked
exocytotic events were detected ampero-
metrically. Values are the average spike
frequency in the first minute after drug
application 6S.E. for measurements from
at least 5 different cells for each point.
FIG. 5. Changes in [Ca21]i induced by transient exposure to
VMAT inhibitors. Ratiometric Fura-2 traces from single cells show
[Ca21]i responses to pressure ejection for 10 s of reserpine (90 nM) or
tetrabenazine (10 mM). Responses are compared with those induced by
60 mM K1. RES, reserpine; TBZ, tetrabenazine.
TABLE I
Spike frequency evoked by caffeine and reserpine in Ca21-free buffers
containing 100 nM thapsigargin, 50 mM ruthenium red, 50 mM
BAPTA-AM, and 0.5 mM EGTA
The cells that were treated with 100 nM thapsigargin for about 5 min
were first permeabilized with 1 mM digitonin. To investigate Ca21 stores
in mitochondria, cells were permeabilized by incubation with 1 mM
digitonin for 4 min to allow entry of 50 mM ruthenium red. Cells treated
with 50 mM BAPTA-AM for 10 min and maintained in a Ca21-free buffer
were used to investigate fast, internal chelation effects. For the buffer
containing 0.5 mM EGTA, the cells were stimulated in that buffer after
a 5-min incubation. Spike frequency was determined for 2-min intervals
after the secretagogue was applied to the cell via a pressure ejection
pipette. The values for spike frequency are average 6S.E. (spikes/min).
Secretagogue
Ca21-free buffers
Spike frequency (no. of cells tested)
10 mM CAF 9 nM RES
Controls, no chelator 9.00 6 0.25 (6) 10.50 6 0.34 (6)
Thapsigargin 4.67 6 0.67 (5)a 8.67 6 0.56 (5)b
Ruthenium red 7.40 6 0.51 (6)a 9.80 6 0.66 (6)
BAPTA-AM 4.89 6 0.39 (9)a 4.00 6 0.00 (4)b
EGTA 8.00 6 0.40 (9) 8.00 6 0.27 (8)b
a ANOVA reveals value is statistically different from value with 10
mM caffeine in Ca21-free buffer (p # 0.016, degrees of freedom $ 11).
b ANOVA reveals value is statistically different from value with 9 nM
reserpine in Ca21-free buffer (p $ 0.019, degrees of freedom $ 9).
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fusion and docking steps of the secretory process (31). A num-
ber of reports suggest a physiologically relevant role for vesic-
ular calcium in exocytosis (1, 4, 32). Gerasimenko et al. (33)
observe that cyclic ADP-ribose and inositol 1,4,5-triphospate
treatment of isolated zymogen granules led to a rapid efflux of
stored Ca21, implicating these storage granules as the Ca21
source for the agonist-induced rise in cytoplasmic Ca21 ob-
served in pancreatic acinar cells. In several preparations, an
inhibitor of vesicular calcium storage enhanced acetylcholine
release, suggesting a role for synaptic vesicles in buffering of
local calcium concentrations at sites of exocytosis (2).
In previous work, we demonstrated that alkalinization of the
vesicle interior can cause efflux of vesicular Ca21 to the cyto-
plasm in adrenal chromaffin cells and that the amounts of Ca21
released from this source are sufficient to elicit exocytosis (9).
In this work, we examined the effects of reserpine and tetra-
benazine, specific inhibitors of the vesicular monoamine trans-
porter (11–14), upon release and Ca21 mobilization from vesi-
cles. Incubations with these agents for 15 min decreased both
the exocytotic frequency and amount released per event evoked
by exposure to depolarizing agents (Fig. 2), similar to that seen
at PC12 cells (34). The decreased spike frequency is not simply
a reflection of a shift in spike amplitudes toward smaller,
undetectable, values after incubation, since the amperometric
traces were purposely over-filtered to facilitate detection of
small spikes.
However, the data also indicate that the VMAT inhibitors
are releasing internal Ca21 in quantities sufficient to evoke
exocytotic release. The decreased [Ca21]i evoked by depolaring
agents following long term incubation, the exocytosis evoked by
transient exposure to reserpine and tetrabenazine, and the
increase in [Ca21]i evoked by reserpine all indicate that VMAT
inhibitors are capable of altering a Ca21 storage pool that plays
a significant role in stimulated secretion. The ability of reser-
pine and its analogs to cause exocytosis, efflux of cat-
echolamines into the cytoplasm (Fig. 3B), and to decrease nic-
otine-evoked exocytosis correlates well with their potencies as
inhibitors of vesicular storage via VMAT (35, 36). Methyl re-
serpate is both less lipophilic and less potent than reserpine as
an inhibitor of VMAT (12), whereas reserpic acid has a very low
inhibitory potency, and its water solubility is relatively high
(27). Since incubation of isolated chromaffin vesicles with
VMAT inhibitors causes a decrease in [Ca21]vesicle (Fig. 3A), the
results strongly suggest that this storage pool is the vesicles
themselves. Furthermore, the direct correlation between di-
minished nicotine-evoked cytoplasmic Ca21 levels and fre-
quency of exocytosis after long term incubation with VMAT
inhibitors suggests that this reserpine-sensitive Ca21 store is
normally involved in exocytosis.
The dynamic interaction between Ca21 entry and intracellu-
lar stores plays an important role in sustaining release (37).
The most well characterized mechanism for exocytosis is ele-
vation of [Ca21]i arising from influx of Ca
21 though voltage-
gated or ligand-operated Ca21 channels (38). However, when
this source of Ca21 is no longer available, Ca21 from intracel-
lular stores can evoke exocytosis (19, 39). The mobilization of
intracellular Ca21 in bovine chromaffin cells also can lead to
the opening of Ca21 channels in the plasma membrane to
admit Ca21 from the exterior (40). Vesicles have been found to
dock near these Ca21 channels (19). This proximity to the
source would enable a small amount of Ca21 released from a
vesicle either to trigger influx of external Ca21 or to initiate
and to potentiate exocytosis. Consistent with this effect, the
reserpine-induced exocytotic frequency is reduced, but not
eliminated, in Ca21-free medium, where influx of external
Ca21 is greatly diminished. Chelation of internal Ca21 by
BAPTA-AM further lowers reserpine-evoked exocytosis (Table
I). This decrease in frequency supports an internal Ca21 source
that would cause a small rise in localized Ca21 even though
changes in intracellular Ca21 levels were undetected with
Fura-2, an indicator of global rises in [Ca21]i. A small, localized
Ca21 source such as a vesicle could induce other vesicles within
close proximity to fuse with the plasma membrane. The pro-
teins that enable this fusion half maximally bind Ca21 in the
micromolar range (41–43). However, this localized rise in Ca21
levels would only be high sufficient to affect the readily releas-
able pool (44).
An important question arising from results presented here is
the mechanism for Ca21 mobilization by VMAT inhibitors from
chromaffin vesicles. Reserpine is a highly lipophilic and very
potent inhibitor of vesicular catecholamine transport (45, 46).
At high concentrations (.200 pmol/mg of membrane protein) it
may act as a detergent, causing release of freely diffusable
substance within the vesicle (47). However, all of the concen-
trations utilized in pressure ejection were below this value (a
5-s, 90 nM pressure ejection corresponds to 163 pmol/mg of
membrane protein), making a detergent action unlikely. An-
other possible mechanism is direct interaction of inhibitors
with an ion channel or pump involved in Ca21 mobilization or
storage. Mahata et al. (48) describe a dose dependent reserpine-
induced release of norepinephrine from PC12 and bovine chro-
maffin cells preloaded with the radiolabeled catecholamine and
reserpine inhibition of secretion stimulated by nicotine or
membrane depolarization (48). Although attributed to an inhi-
bition of L-type Ca21 channels, no demonstration of a direct
inhibitory action on channel currents by reserpine or tetraben-
azine was provided.
FIG. 6. Release in Ca21-free medium. A, amperometric response
following pressure ejection of 10 mM caffeine (CAF) and 9 nM reserpine
(RES) onto the same cell in Ca21-free medium. B, a cell was permeabi-
lized with 1 mM digitonin for 5 min and then incubated with 100 nM
thapsigargin for 5 min in the absence of Ca21. Amperometric recordings
were made during pressure ejection of 10 mM caffeine and 9 nM reser-
pine in the absence of Ca21. C, prior to the traces the cell was perme-
abilized by incubation with 1 mM digitonin for 5 min in Ca21-free buffer
and then incubated with 50 mM ruthenium red for another 5 min.
During the amperometric recordings, 10 mM caffeine and 9 nM reserpine
were applied onto the cell via pressure ejection. At each cell, 2 min
elapsed between caffeine and reserpine drug exposure.
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A third possibility and one we consider more likely is that
efflux of both Ca21 and catecholamine results directly or indi-
rectly from inhibition of VMAT. Michalke et al. (35) proposed a
“pump and leak system” involving reserpine-sensitive accumu-
lation but reserpine-insensitive catecholamine efflux as a re-
sult of studies on chromaffin granule ghosts. Two efflux mech-
anisms were observed in highly purified synaptic vesicles from
rat brain (36); one was inhibited by reserpine and tetrabena-
zine, whereas the other was not. These leak pathways may also
directly mobilize calcium. Alternatively, the inhibitor-induced
efflux of catecholamines from the vesicle could cause Ca21
mobilization by perturbation of the vesicle matrix. The matrix
of the vesicle is composed of chromogranins, catecholamine,
Ca21, Mg21, and ATP that make up a noncrystalline, partially
dehydrated gel-like polymer that confers osmotic stability de-
spite the high concentrations of solutes within the vesicle (49,
50). Since the decrease in the free catecholamine concentration
within the vesicle would alter catecholamine matrix associa-
tion, this may alter the binding of Ca21 to the matrix as well.
Indeed, reserpine and tetrabenazine treatment of bovine chro-
maffin cells leads to a decrease in ATP, another component of
the vesicular matrix (13). Similarly, removal of vesicular Ca21
with the selective ionophore, A23187, causes isolated vesicles
to dissociate (51). Changes in vesicle pH have profound effects
on the association of the vesicle components (7, 52) and account
for effects of amine weak bases on secretion and Ca21 mobili-
zation observed previously (9).
In summary, the results here and our prior work with weak
bases show that Ca21 from vesicles can participate in the
induction of exocytosis. Indeed, as shown here, incubations
with amphetamine lead to a decreased frequency of release
that is accompanied by decreased quantal size and decreased
nicotine-evoked [Ca21]i, behaviors identical to that of the
VMAT inhibitors. Although the VMAT inhibitors and weak
bases have similar effects, the underlying mechanisms for Ca21
mobilization in each case probably differs. However, the results
with both classes of drugs clearly show that alteration of ve-
sicular catecholamine content is accompanied by liberation of
sufficient Ca21 to cause exocytosis. More importantly, it ap-
pears that this source of Ca21 normally participates in the
catalysis of exocytosis since the exocytotic rate decreases when
the store is diminished. Thus, chromaffin cells as well as other
secretory cells share the attribute that the trigger for vesicle-
plasma membrane fusion is contained within the vesicle.
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29. Gonçalves, P. P., Meireles, S. M., Gravato, C., and Vale, M. G. P. C. (1998)
Neurosci. Letts. 247, 87–90
30. Han, W., Danqing, Li., Stout, A. K., Takimoto, K., and Levitan, E. S. (1999)
J. Neurosci. 19, 900–905
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